Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04686786 · ClinicalTrials.gov registry record · Phase 2
An Open-label Extension Trial of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures
A Phase 2 study, sponsored by AbbVie.
- Terminated
- Registry status
- Phase 2
- Development phase
- 105
- Enrollment target
NCT04686786 is a Phase 2 study that was terminated before completion, run by AbbVie. The registered enrollment target is 105 participants.
The verdict
NCT04686786, a Phase 2 study, was terminated before completion, sponsored by AbbVie.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 105 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the long-term safety and tolerability of CVL-865 as adjunctive therapy in participants with focal onset seizures.
Interventions
- DRUG CVL-865
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Start Date | 2020-12-08 |
| Est. Completion | 2024-12-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04686786
The ClinicalTrials.gov registry entry for NCT04686786 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 105 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CVL-865 is the first listed.
NCT04686786 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04686786 about?
NCT04686786 is a clinical study titled "An Open-label Extension Trial of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures". The purpose of this study is to assess the long-term safety and tolerability of CVL-865 as adjunctive therapy in participants with focal onset seizures.
What is the current status of trial NCT04686786?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 105 participants. The study started on 2020-12-08. Estimated completion is 2024-12-05.
What interventions are being tested in trial NCT04686786?
The interventions under investigation include: CVL-865 (DRUG).
Who is sponsoring clinical trial NCT04686786?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.